Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor in Chronic Lymphocytic Leukemia and Multiple Myeloma. 50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium Wierda, W. G., Chen, R., Plunkett, W., Coutre, S., Badros, A. Z., Popplewell, L., Siegel, D., Sinha, R., Harvey, D., Fox, J., Mahadocon, K., Kegley, P., Bolton, M. G. AMER SOC HEMATOLOGY. 2008: 1090–90
View details for Web of Science ID 000262104703615